This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Drug Stocks Unworthy of Biotech Bull Market

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Cytori Therapeutics (CYTX - Get Report)

Stock return since Jan. 1: 96%

Cytori's base business of selling machines and related consumables that turn belly blubber into stem cell- enriched fat grafts for breast reconstruction and other soft tissue repair is hurting. While fourth-quarter results haven't been released yet, lower-than-expected sales in the third quarter and mounting losses offer little hope of a turnaround from what was a bad 2011.

Simply put, Cytori is having trouble convincing doctors in Europe and Japan to buy their expensive stem-cell fat graft machines. And even when doctors do buy the device, they're not using it very much, or at all, because procedures aren't being reimbursed. (Most likely because Cytori has yet to provide convincing clinical data to prove that stem cell-enriched belly fat is superior in any way to "regular" fat.")

The U.S. remains a closed market for Cytori because regulators here won't allow the company's machine to be sold without first demonstrating a real clinical benefit for patients.

Meantime, Cytori continues to burn cash and raise money though dilutive stock sales in order to keep its unprofitable business afloat. Simultaneously, the company is funding large, expensive clinical trials in indications like heart repair following heart attack that will take years to fully enroll.

Cytori shares closed Tuesday down 6% to $4.05.
2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CYTX $0.15 -16.00%
ENMD $0.90 0.00%
GALE $0.65 3.40%
REGN $385.73 -2.70%
BPAX $55.05 -1.24%


Chart of I:DJI
DOW 15,935.96 -269.01 -1.66%
S&P 500 1,848.75 -31.30 -1.66%
NASDAQ 4,269.3630 -93.7810 -2.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs